<DOC>
	<DOCNO>NCT00559351</DOCNO>
	<brief_summary>The purpose study test null hypothesis combine modality treatment esophageal cancer neoadjuvant chemotherapy chemoradiotherapy equivalent surgery alone benefit add irradiation chemotherapy neoadjuvant treatment esophageal cancer .</brief_summary>
	<brief_title>RCT Combined Modality Treatment Squamous Cell Carcinoma Esophagus</brief_title>
	<detailed_description>The choice beneficial method treatment esophageal cancer remain controversial subject vigorous debate . Surgery still regard principle modality among treatment strategy , longterm survival achieve mainly less advanced case . More advanced case , diagnose frequently , problematic selection optimal therapeutic method . One option improve treatment outcome patient advanced esophageal cancer combine modality treatment chemo- chemoradiotherapy . Currently available RCTs test preoperative chemotherapy chemoradiotherapy separately comparison surgery alone . Moreover , know trial add value irradiation combine modality therapy preoperative chemotherapy . Another drawback available RCTs combine 2 different biological cancer entity : adenocarcinoma squamous cell carcinoma esophagus well carcinoma esophagus gastro-esophageal junction . That reason design trial test 3 principal mode esophageal cancer therapy : surgery vs. chemotherapy + surgery vs. chemoradiotherapy + surgery homogenous population esophageal cancer patient single pathological type - squamous cell carcinoma affect thoracic esophagus .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Informed consent Histopathologically proven , clinically stage IIIII ( cTNM accord AJCC/UICC classification ) , primary squamous cell carcinoma thoracic esophagus Patients ' age 18 year General condition Karnofsky performance status &gt; 70 Circulatory pulmonary capacity normal range ( FEV1 &gt; 60 % ; FVC &gt; 60 % , NYHA III , cardiac output &gt; 40 % ) Normal function bone marrow ( RBC &gt; 3,5 T/l ; PLT &gt; 100 G/l ) Normal renal ( creatinine &lt; 1.5 upper limit ) liver ( AST ALT &lt; 2,5 upper limit bilirubin &lt; 1,5 upper limit ) function Metastatic disease Synchronous malignancy History cancer within 5 year prior esophageal cancer treatment History allergic reaction cisplatin 5fluorouracil Systemic infection Pregnancy female patient childbearing age without proper contraceptive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>esophagectomy</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>chemoradiotherapy</keyword>
	<keyword>combine modality therapy</keyword>
</DOC>